statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results...

Bausch + Lomb Announces First-Quarter 2024 Results

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster...

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published...

Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue Eye Care Recycling...

Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on...

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

DAVENPORT & Co LLC decreased its holdings in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange...

DAVENPORT & Co LLC Decreases Holdings in Bausch + Lomb Co. (NYSE:BLCO)

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations...

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

In trading on Wednesday, shares of Bausch + Lomb Corporation (BLCO) crossed above their 200 day moving average of 16.98, changing hands as high as 17.37 per share. Bausch + Lomb...

BLCO Crosses Above Key Moving Average Level

Bausch + Lomb Co. (NYSE:BLCO  Get Free Report) has earned an average recommendation of Moderate Buy from the ten research firms that are covering the stock, MarketBeat.com...

Bausch + Lomb Co. (NYSE:BLCO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Bausch + Lomb Co. (NYSE:BLCO  Get Free Report) have received a consensus recommendation of Moderate Buy from the ten research firms that are covering the stock...

Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Target Price at $19.68

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Volume	1.16M
52-Wk High	$21.95
52-Wk Low	$13.16

BLCO Bausch + Lomb Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community